Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mayo clinic pinpoints nonirritating doses for allergy testing of three common anesthesia drugs

NCT ID NCT07103720

Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 4 trial at Mayo Clinic tested 21 healthy adults to find the highest skin-testing concentrations of midazolam, ketamine, and ondansetron that do not cause irritation. These drugs are commonly used before, during, and after surgery. The goal is to improve allergy testing accuracy for patients who may have life-threatening reactions during anesthesia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
midazolam, ketamine, ondansetron
What this could lead to
If successful, this study could help doctors safely test for drug allergies during anesthesia, reducing false positives and improving patient safety.
What could go wrong
This is a small, completed study in healthy volunteers, so results may not apply to all patients. It only establishes nonirritating concentrations, not treatment or prevention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

21 people

The number who actually took part.

Started

Nov 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Not have a history of an adverse reactions to midazolam, ketamine or ondansetron * Ability to understand study procedures and to comply with them for the entire length of the study. * Contraception is not necessary, and we will include women of reproductive capability. Exclusion Criteria: * Unstable patients. * History of any adverse reaction (allergy or sensitivity) to midazolam, ketamine or ondansetron. * Pregnant and Pediatric patients * Inability or unwillingness of individual or legal guardian/representative to give written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergy

Contacts and locations

Locations

  • Mayo Clinic Arizona

    Scottsdale, Arizona, 85268, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.